Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
- 1 April 2006
- journal article
- Published by Elsevier in The Breast
- Vol. 15 (2) , 219-225
- https://doi.org/10.1016/j.breast.2005.04.017
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBritish Journal of Cancer, 2004
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- First-Line Herceptin® Monotherapy in Metastatic Breast CancerOncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Herceptin®: increasing survival in metastatic breast cancerEuropean Journal of Oncology Nursing, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Central nervous system metastasis from breast carcinoma autopsy studyCancer, 1983
- The natural history of breast cancer patients with brain metastasesCancer, 1979